Stock Market Today, April 6: Soleno Therapeutics Climbs After $2.9 Billion All-Cash Buyout Agreement [Globe and Mail, The (Toronto, Canada)]
Neurocrine Biosciences, Inc. (NBIX)
Last neurocrine biosciences, inc. earnings: 2/4 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
neurocrine.com/about-us/webcasts-presentations
Company Research
Source: Globe and Mail, The
Biosciences' (NASDAQ:NBIX) $53-per-share all-cash acquisition offer for Soleno. Investors are watching for any deal-related regulatory or closing risks. Trading volume reached 58 million shares, coming in about 2,148% above its three-month average of 2.6 million shares. Soleno Therapeutics IPO'd in 2014 and has fallen 96% since going public. How the markets moved today The S&P 500 gained 0.43% to finish Monday at 6,611, while the Nasdaq Composite added 0.54% to close at 21,996. Among biotechnology industry peers, Rezolute closed at $3.26, up 4.49%, and Ligand Pharmaceuticals ended at $203.61, rising 1.61%, as deal activity and drug data kept the group in focus. What this means for investors Neurocrine Biosciences reinforced its rare-disease drug portfolio on Monday, acquiring Soleno Therapeutics and its VYKAT XR treatment for hyperphagia in patients with Prader-Willi Syndrome (PWS). Soleno's main drug, the first and only FDA-approved treatment for hyperphagia in patients with
Show less
Read more
Impact Snapshot
Event Time:
NBIX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NBIX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NBIX alerts
High impacting Neurocrine Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
NBIX
News
- Why Soleno Therapeutics Stock Rocketed Higher on Monday [Yahoo! Finance]Yahoo! Finance
- Neurocrine Biosciences (NBIX) had its "buy" rating reaffirmed by Needham & Company LLC. They now have a $185.00 price target on the stock.MarketBeat
- Neurocrine Biosciences Details $2.9B Soleno Buyout, Touts Vykat XR as Potential Blockbuster [Yahoo! Finance]Yahoo! Finance
- Neurocrine Biosciences, Inc. (NBIX) M&A Call Transcript [Seeking Alpha]Seeking Alpha
- Neurocrine to acquire Prader-Will drug in $2.9B Soleno buyout [Yahoo! Finance]Yahoo! Finance
NBIX
Earnings
- 2/11/26 - Beat
NBIX
Sec Filings
- 4/6/26 - Form 8-K
- 3/27/26 - Form SCHEDULE
- 3/17/26 - Form 3
- NBIX's page on the SEC website